Compare MDBH & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MDBH | MDXH |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 18.5M |
| IPO Year | 2022 | 2021 |
| Metric | MDBH | MDXH |
|---|---|---|
| Price | $1.66 | $0.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $0.83 |
| AVG Volume (30 Days) | 4.5K | ★ 1.7M |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.81 |
| Revenue Next Year | N/A | $13.37 |
| P/E Ratio | $4.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.16 |
| 52 Week High | $4.16 | $4.86 |
| Indicator | MDBH | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 36.25 | 22.98 |
| Support Level | N/A | N/A |
| Resistance Level | $3.17 | $0.66 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 46.62 | 0.00 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.